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Abstract
The aim of this article is to report on antimicrobial resistance (AMR) in commensal Escherichia coli from livestock from several 
European countries. The relationships with antimicrobial usage (AMU) at country level and harmonized indicators to cover the 
most relevant AMR aspects for human health in animal production were also investigated. E. coli were isolated in faeces from 
broilers and fattening pigs (from nine countries), and fattening turkeys and veal calves (from three countries) and screened 
against a fixed antimicrobial panel. AMU data were collected at farm and average treatment incidences stratified by antimicro-
bial class, country and livestock species were calculated. Associations between AMR and AMU at country level were analysed. 
Independent of animal species, the highest resistance was observed for ampicillin, sulphamethoxazole, tetracycline and tri-
methoprim. E. coli from broilers showed the highest resistance level for (fluoro)quinolones, and multidrug resistance peaked in 
broilers and fattening turkeys. Colistin resistance was observed at very low levels with the exception of fattening turkeys. High 
resistance to third- and fourth- generation cephalosporins was detected in broilers and fattening turkeys. The lowest levels of 
resistance were for meropenem, azithromycin and tigecycline (<1 %). Significant correlations between resistance and usage at 
country level were detected in broilers for polymyxins and aminoglycosides, and in fattening pigs for cephalosporins, ampheni-
cols, fluoroquinolones and polymyxins. None of the correlations observed between AMR and AMU were statistically significant 
for fattening turkey and veal calves. The strength of the analysis performed here is the correlation of aggregated data from the 
same farms at country level for both AMU and AMR within antimicrobial classes.
DATA SUMMARy
The authors confirm all supporting data, code and protocols 
have been provided within the article or through supplemen-
tary data files.
INTRODUCTION
Antimicrobial resistance (AMR) has emerged globally in 
food- producing animals during the last decades, with conse-
quent concerns for both veterinary and human medicine 
[1]. The AMR reservoir in bacteria from livestock has been 
increasingly investigated for its potential to transfer AMR to 
humans via direct contact, the environment or the food- chain 
[2, 3]. AMR is not an issue only for pathogenic bacteria but 
also for commensal intestinal microbiota. Escherichia coli is 
commonly used as an indicator of the Gram- negative gut 
microbiota [4]. Most livestock carry E. coli as a commensal 
in their intestine and thus it can be regarded as a reservoir 
of acquired resistance determinants. Phenotypic assessment 
of E. coli is used as a proxy of AMR in the intestinal tract of 
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healthy animals, including resistance determinants mediated 
by mobile genetic elements. This approach is crucial in moni-
toring activities in Europe as recommended by the European 
Food Safety Authority (EFSA) [5].
In the EU FP7 EFFORT project (http://www. effort- against- 
amr. eu/), a cross- sectional analysis of antimicrobial resistance 
and antimicrobial usage (AMU) was conducted in a selection 
of broilers and fattening pigs farms in nine EU countries. In 
three countries, the occurrence and characteristics of AMR 
and AMU was also analysed in a selection of veal calf and 
fattening turkey farms. The strength of the EFFORT project 
relies on the fact that both AMR and AMU datasets were 
gathered from the same farms, making this data explicitly 
suitable to analyse overall correlations between AMR and 
AMU. Conversely, in monitoring activities, this is more 
difficult since AMR data are collected at slaughterhouse, 
while AMU data are available from different farms, there-
fore, not from the same epidemiological units. The data was 
also analysed considering harmonized indicators in food- 
producing animals proposed by EFSA and the European 
Centre for Disease Control (ECDC) to estimate the progress 
made towards a reduction in bacterial resistance to key anti-
microbials in livestock within the European Union [5]. One 
primary indicator (full susceptibility) and three secondary 
indicators (resistance to third- and fourth- generation cepha-
losporins, multidrug resistance and ciprofloxacin resistance) 
can be used to provide a general assessment of the overall 
AMR situation in each nation and information on specific 
issues of a more restrict scope, respectively [5].
The aim of this paper is to report on antimicrobial resistance 
prevalence in indicator E. coli, as well as on the overall correla-
tion between resistant proportions of isolates and mean AMU 
per country from farms sampled within the EFFORT project. 
Furthermore, the correlation of mean AMU per country with 
national harmonized indicators per animal species to cover 
the most relevant AMR aspects for human health in animal 
production at national level is analysed.
MeTHODS
Farm selection and animal sampling
Farm selection and sampling has been previously described 
[6]. Briefly, for each of the participating countries (Belgium, 
Bulgaria, Denmark, France, Germany, Italy, the Netherlands, 
Poland and Spain) 20 conventional integrated farrow- to- 
finisher pig farms and 20 conventional broiler farms were 
included. Countries were anonymized (A to I) to ensure that 
results could not be traced back and because farm selections 
cannot be considered representative of an entire country. 
However, the sample size of species at country level does 
allow showing an approximation of the problem, including 
differences at species level and trends at country level when 
it comes to AMR and AMU. Furthermore, 20 conventional 
turkey farms with an all- in all- out system (countries B, E and 
H) and 20 non- mixed white or rosé veal calf farms with an 
all- in all- out system at the compartment level (countries B, E 
and F) were included. These two datasets were incorporated in 
the original EFFORT project based on the relevance of these 
specific livestock production from a national point of view, 
and because of the scarce data available on AMU and AMR in 
veal calves and fattening turkeys, especially in a multi- country 
setting. In order to standardize methods and techniques 
during a pilot study, one additional farm for both fattening 
pigs and broilers (30 instead of 10 animals per farm, country 
A) and veal calves (10 animals, country B) were included. All 
farms included in the study were epidemiologically unrelated, 
as the farms were required not to have contact with each other 
through trade and each farm had only one owner.
Faecal samples from ten animals per farm (1830 broilers, 1830 
fattening pigs, 600 fattening turkeys and 610 calves) were 
collected within the last week before slaughter. To prevent 
seasonal influences farm sampling was distributed over the 
year, sampling five farms per season. Overall sampling in all 
countries was conducted between April 2014 and October 
2016. Deviations from sampling protocol are described in 
detail by Munk and colleagues [6]. For each farm, faecal 
samples were suspended in Buffered Peptone Water (BPW) 
[1 : 10 (w/v)] with 20 % glycerol and from each sample a 
volume of 2 g was stored in duplicate at −80 °C.
E. coli isolation and susceptibility testing
Faecal samples were individually inoculated on MacConkey 
agar without antibiotic selection at 37 °C. After overnight 
incubation, one randomly picked presumptive E. coli colony 
per faecal sample, per farm, was pure cultured and stored 
individually in BPW with 20 % glycerol at −80 °C pending 
analysis. Colonies were confirmed as E. coli biochemically 
or alternatively by MALDI- TOF MS (Microflex LT MALDI 
Biotyper; Bruker Biosciences) or sub- culturing onto CHRO-
Magar (CHROMagarTM).
MICs with broth microdilution were determined for a fixed 
panel of antimicrobials by commercially available microtitre 
plates (EUVSEC, Thermo Fisher Scientific). Quality assurance 
among laboratories was ensured by distribution of a Standard 
Operating Procedure according to ISO standard 20776-1-
2006 [7], use of ATCC strains as control, and standardization 
of methodologies during a mandatory training organized 
before sample collection. Within EFFORT, no External 
Quality Assurance Service (EQAS) was organized because 
the majority of laboratories involved are National Reference 
Laboratories that already take part in the annual EQAS organ-
ized by the EU Reference Laboratory – Antimicrobial, hosted 
at DTU- Food (DK), also one of the participating laboratories 
in EFFORT.
EUCAST epidemiological cut- off values were used to differ-
entiate between wild- type and non- wild- type susceptibility 
(henceforward referred to as resistant isolates). The epide-
miological cut- off values (ECOFFs) used were as follows: 
ampicillin (AMP) ≤8 mg l−1, cefotaxime (FOT) ≤0.25 mg l−1, 
ceftazidime (TAZ) ≤0.5 mg l−1, meropenem (MERO) ≤0.125 
mg l−1, ciprofloxacin (CIP) ≤0.064 mg l−1, nalidixic acid (NAL) 
≤16 mg l−1, azithromycin (AZI) ≤16 mg l−1, chloramphenicol 
(CHL) ≤16 mg l−1, colistin (COL) ≤2 mg l−1, gentamicin 
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Fig. 1. Antimicrobial resistance proportions (%) of E. coli isolated from broilers, fattening pigs, fattening turkeys and veal calves per 
country. AMP: ampicillin; FOT: cefotaxime; TAZ: ceftazidime; MERO: meropenem; CIP: ciprofloxacin; NAL; nalidixic acid; AZI: azithromycin; 
CHL: chloramphenicol; COL: colistin; GEN: gentamicin; SMX: sulphamethoxazole; TMP: trimethoprim; TET: tetracycline; TGC: tigecycline.
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Fig. 2. Average antimicrobial usage (TI/1000) in sampled farms for broilers, fattening pigs, fattening turkeys and veal calves per country. 
Aminogly: Aminoglycosides; Aminopen: Aminopenicillins; Amph: Amphenicols; Ceph: Cephalosporins; Fluoroq: Fluoroquinolones; Linco: 
Lincosamides; Linco_Spect: Lincomycin- Spectinomycin; Macro: Macrolides; Other Q: Other quinolones; Parom: Paromomycin; Pen: 
Penicillins; Pleurom: Pleuromutilins; Polymix: Polymyxins; Sulpho: Sulphonamides; Tetra: Tetracyclines; Trim_Sulpha: Trimethoprim- 
Sulphonamides.
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(GEN) ≤2 mg l−1, sulphamethoxazole (SMX) ≤64 mg l−1, 
trimethoprim (TMP) ≤2 mg l−1, tetracycline (TET) ≤8 mg 
l−1 and tigecycline (TGC) ≤0.5 mg l−1 [8]. Misinterpretation 
of sulphamethoxazole MIC- endpoints (overestimation of 
resistance) for country B led to the exclusion of these data 
from the analysis (Table S1, available in the online version 
of this article).
Antimicrobial usage data
Antimicrobial usage data for the following antimicrobial 
classes were obtained for all livestock (unless otherwise 
specified): aminoglycosides, aminopenicillins, amphenicols 
(fattening turkeys excluded), cephalosporins (fattening 
pigs and veal calves only), fluoroquinolones, lincomycin- 
spectinomycin, lincosamides (fattening pigs and broilers 
only), macrolides, other quinolones, paromomycin (fattening 
pigs only), penicillin, pleuromutilins (fattening pigs only), 
polymyxins, tetracycline, sulphonamides (fattening pigs and 
veal calves only) and different combinations of trimethoprim- 
sulphonamides. Group treatment data were collected at farm 
level using specific questionnaires per animal species (ques-
tionnaire for broiler farms is provided as an example in Table 
S2) and were quantified with the treatment incidence (TI) 
indicator. Briefly, TI was calculated as the antimicrobial dose 
per defined daily animal doses (DDDvet) per 1000 animals at 
risk. As TI is expressed per 1000 animals at risk, this number, 
when divided by 10, represents the percentage of their lifetime 
that the animals received a daily dose of antimicrobials. TI 
results are described in more detail per 100 animals at risk 
elsewhere [9, 10]. The TI formula adjusts the total amount 
of active substance administered for the average duration 
of one production cycle on country level in the case of the 
broiler farms [9], and on farm level in the case of the veal 
calf and turkey farms. For pig farms, duration of a produc-
tion cycle was age category- specific (sucklers, weaners and 
finishers). The TI of sucklers, weaned piglets and finishers 
were combined and recalculated into a standardized lifespan 
of 200 days to express AMU from birth to slaughter (TI200) 
[10]. In addition, TI takes into account a standardized dose 
and the number of animals at risk for being treated. The latter 
was derived from the questionnaire where we recorded the 
group size of the animals. Corrections for a standardized dose 
were made by using DDDvet values from ESVAC (European 
Surveillance of Antimicrobial Consumption) for quantifica-
tion in broilers, pigs and veal calves. Whenever DDDvet 
was not available for a product, dosage mentioned in the 
SPC (summary of product characteristics) of that product 
was used. DDDturkey was defined for all antimicrobials used 
on the participating turkey farms, using a similar approach 
as previously described [11]. In this study, average TIs on 
participating farms stratified by antimicrobial class, country 
and livestock species were used.
Statistical analysis
For all livestock species, MIC data were aggregated at country 
level in resistance proportions. AMU data were aggregated 
as mean treatment incidence on participating farms. The 
aggregated MIC data were correlated to the mean treatment 
incidence per country, over countries, giving insight on the 
overall correlations of AMU and AMR within antimicrobial 
classes.
The correlation between AMR proportions and mean AMU 
per country was tested using the Spearman rank correla-
tion test (rho) in RStudio, version 1.1.423. Each antibiotic 
resistance proportion was tested against up to three different 
antimicrobial treatments (T1, T2, T3) depending on the 
available AMU data per animal species: AMP, FOT, TAZ: 
penicillins (T1), aminopenicillins (T2), cephalosporins (T3, 
only for fattening pigs); AZI: macrolides (T1), lincomycin- 
spectinomycin (T2), lincosamides (T3); CHL: amphenicols 
(T1); CIP, NAL: fluoroquinolones (T1), other quinolones 
(T2); COL: polymyxins (T1); GEN: aminoglycosides (T1), 
lincomycin- spectinomycin (T2), paromomycin (T3, only for 
fattening pigs); SMX: trimethoprim- sulphonamides (T1), 
sulphonamides (T2); TET: tetracyclines (T1); TGC: tigecy-
clines (T1); TMP: trimethoprim- sulphonamides (T1). All 
statistical analyses were performed in R version 3.4.3 [12] 
under the integrated development of R- studio.
ReSUlTS AND DISCUSSION
E. coli isolation was successful for all but 34 out of 4860 faecal 
samples. MIC values for 4826 E. coli from broilers (n=1811), 
fattening pigs (n=1809), fattening turkeys (n=596) and veal 
calves (n=610) were included in this study (Table S1). A large 
variation in resistance proportions among antimicrobials, 
countries and animal species was observed (Fig. 1). Substan-
tial differences between countries were also observed at the 
level of antimicrobial usage (Fig. 2).
The results are discussed initially by antibiotic class (AMR and 
AMU) and then in correlation to the four harmonized indica-
tors proposed by EFSA. For fattening pigs and veal calves 
no statistically significant correlation was observed between 
any class of AMR and AMU (data not shown); this is most 
probably due to the small sample size of only three countries.
Independent of the animal species, the highest levels of 
resistance were observed for ampicillin, sulphamethoxazole, 
tetracycline and trimethoprim, which is in line with previous 
studies [13–15].
Resistance to ampicillin in broilers varied between 39.5 and 
92 % (Fig. 1) and strongly correlated (Spearman's rho=0.917, 
P=0.001) with aminopenicillins usage over countries, but 
not with penicillin (Table 1). Resistance to ampicillin in 
fattening pigs (17.5–73.8 %) did not correlate with either 
penicillins or aminopenicillins (Table 1). Because penicillin 
as such does not select for ampicillin resistance in E. coli 
it is not surprising that penicillin treatment (T1) does not 
correlate to ampicillin resistance in either animal species. As 
for the difference observed in correlation between ampicillin 
resistance and aminopenicillins use in broilers and fattening 
pigs, time could be the most likely explanation. The interval 
between amoxicillin use in young broilers and their slaughter 
age (6 weeks) is very short compared to the relatively long 
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interval in pig production, considering the use of amoxi-
cillin in sows at delivery and in piglets to control bacterial 
infections (i.e. Streptococcus suis), and the slaughter age of 
pigs. Surprisingly, resistance to ampicillin in fattening pigs 
correlated significantly (Spearman's rho=0.729, P=0.026) 
with cephalosporins usage over countries. This associa-
tion might be an artefact, since cephalosporins only select 
for resistance to extended spectrum cephalosporins and 
not to ampicillin (as, for example, in the case of TEM-1 
beta- lactamases).
For simplicity, resistance to third - and fourth -generation 
cephalosporins and ciprofloxacin are discussed later in the 
article in correlation with the harmonized indicators proposed 
Table 1.  Correlation between antimicrobial usage (average treatment incidence at farm level stratified per country, species and antimicrobial class) 
and resistance (MIC data aggregated at country level in resistance proportions)
Animal Antimicrobial T1* T2* T3*
rho† p rho p rho p
Broilers AMP 0.548 0.127 0.917 0.001
AZI 0.173 0.656 0.019 0.961 0.217 0.576
CHL 0.000 1.000
CIP 0.778 0.014 −0.138 0.724
COL 0.718 0.029
FOT −0.279 0.468 0.424 0.256
GEN 0.713 0.031 −0.359 0.343
NAL 0.667 0.059 −0.137 0.725
SMX 0.574 0.106
TAZ −0.138 0.723 0.588 0.096
TET −0.153 0.695
TGC −0.471 0.200
TMP 0.809 0.008
Fattening pigs AMP 0.271 0.480 0.417 0.270 0.729 0.026
AZI −0.145 0.709 −0.818 0.007 0.638 0.064
CHL 0.807 0.009
CIP 0.806 0.009 0.279 0.468
COL 0.789 0.011
FOT 0.260 0.500 0.128 0.743 0.329 0.387
GEN −0.035 0.928 −0.315 0.408
NAL 0.698 0.037 0.276 0.472
SMX 0.151 0.699 0.274 0.476
TAZ −0.035 0.928 −0.147 0.705 0.282 0.462
TET −0.126 0.748
TGC −0.594 0.092
TMP 0.494 0.177
In bold, p< 0.05.
*T1, T2 and T3 treatments correspond to the following classes per antimicrobial, respectively: AMP, FOT, TAZ: Penicillins (T1), Aminopenicillins 
(T2), Cephalosporins (T3)#; AZI: Macrolides (T1), Lincomycin- Spectinomycin (T2), Lincosamides (T3); CHL: Amphenicols (T1); CIP, NAL: 
Fluoroquinolones (T1), Other quinolones (T2); COL: Polymyxins (T1); GEN: Aminoglycosides (T1), Lincomycin- Spectinomycin (T2), Paromomycin# 
(T3); SMX: Trimethoprim- Sulphamethoxazole (T1), Sulphonamides (T2); TET, TGC: tetracyclines (T1); TMP: Trimethoprim- Sulphamethoxazole (T1). 
#Only fattening pigs.
†Spearman’s rho.
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by EFSA to assess the most relevant aspects of AMR of public 
health concern in food- producing animals.
Resistance proportions for sulphamethoxazole were highest in 
poultry (82 %, country D) and fattening pigs (77.7 %, country 
I). Tetracycline resistance recorded the highest proportions 
in broilers (89.6 %, country I) and fattening turkeys (92.3 
%, country H). No significant correlations were observed 
between sulphamethoxazole and tetracycline resistance 
and their respective treatment incidents data over countries 
(Table 1). Despite the high resistance levels, tetracycline did 
not belong to the three most used antimicrobials neither in 
broilers nor in fattening pigs [9, 10]. However, part of the 
resistance could be explained by a historical build- up, due to 
heavy use in the past [16], and/or the common occurrence 
of tet and sul resistance genes in E. coli, independently on 
antibiotic usage.
Trimethoprim resistance was highest in broilers (76.5 
%, country D) and significantly correlated (Spearman's 
rho=0.809, P=0.008) with trimethoprim- sulphamethoxazole 
usage over countries (Table 1).
Although nalidixic acid resistance reached its highest levels 
in broilers (86%, country I), no correlation was observed with 
fluoroquinolone usage. Conversely, fluoroquinolone usage 
significantly correlated (Spearman's rho=0.698, P=0.037) 
with resistance in fattening pigs (Table 1).
In spite of a ban on the use of chloramphenicol in animals 
used for food production since the early 1990s [17], resistance 
was high in fattening turkeys (up to 56.1%, country H) and 
fattening pigs (up to 44.5%, country I), with lower proportions 
in broilers (up to 34.5%, country D) and veal calves (up to 22.4%, 
country B) (Fig. 1). In fattening pigs, chloramphenicol resist-
ance significantly correlated (Spearman's rho=0.807, P=0.009) 
with phenicols usage over countries (Table 1). Gentamicin 
resistance in broilers was <10 % in all countries, except for 
country H (45.3%) (Fig.  1). This significantly correlated 
(Spearman's rho=0.713, P=0.031) to no or very low amino-
glycosides usage at sampled farms over countries (Table 1). 
Very low resistance to tigecycline was observed, a drug 
not used in veterinary medicine, whose resistance mecha-
nism is mostly due to efflux pump over- expression [18]. 
Azithromycin resistance was very low or absent in E. coli 
(Fig.  1). The highest prevalence (3.8%, country E) was 
observed in veal calves, where metaphylaxis with macrolides 
is commonly used to control bovine respiratory diseases, 
which may exert selective pressure on commensal intestinal 
microbiota [19]. A high negative correlation (Spearman's 
rho=−0.818, P=0.007) between azithromycin resistance and 
usage of lincomycin- spectinomycin in fattening pigs was 
observed, a phenomenon for which a biological explanation 
is not currently available.
Low proportions were observed for colistin resistance 
in broilers, fattening pigs and veal calves (0–6.5 %), 
conversely to fattening turkeys (8.5–17.5 %). Although 
sales of polymyxin dropped in Europe between 2010 and 
2016 [20], colistin was still substantially used in some 
of the countries involved in this study. In both broilers 
and fattening pigs, polymyxin usage corresponded 
significantly (Spearman's rho=0.718, P=0.029 and Spear-
man's rho=0.789, 0.011, respectively) with the mean 
resistant proportion of isolates over countries (Table 1). 
Meropenem resistance was absent in veal calves and only 
sporadically detected in other animal species (<1.5 %) 
(Fig. 1). Meropenem resistant E. coli isolates were confirmed 
to be negative for carbapenemase genes blaOXA-48, blaNDM, 
blaKPC, blaVIM and blaIMP (data not shown). As carbapenems 
are not licensed for use in livestock, correlation between 
meropenem resistance and aminopenicillins and/or 
cephalosporin usage was tested. No significant correlation 
between antimicrobial usage and resistance was observed 
for broilers and fattening pigs (data not shown).
Four harmonized indicators are proposed by EFSA to assess 
the most relevant aspects of AMR of public health concern 
in food- producing animals: (1) resistance to third- and 
fourth- generation cephalosporins, (2) resistance to cipro-
floxacin, (3) full susceptibility and (4) multidrug resistance 
(Table 2) [5]. The proportion of indicator E. coli resistant to 
third- and fourth- generation cephalosporins is prioritized 
since these antimicrobials are classified as the highest prior-
itized critically important for human medicine [21].
The proportion of E. coli displaying non- wild- type suscep-
tibility to cefotaxime and/or ceftazidime varied by animal 
species and country (Fig. 1). It was low in fattening pigs and 
veal calves (0.5–2.1 %), but reached higher levels in fattening 
turkeys (23.5 %, country H) and broilers (16.6 %, country H) 
(Table 2). Occurrence and prevalence of extended spectrum 
β-lactamase- producing E. coli that may enter the food chain 
varies greatly by animal species and country. No significant 
correlation between resistance to cefotaxime and/or ceftazi-
dime and cephalosporins use was observed in broilers and 
fattening pigs (Table 1), contrarily to what is reported in other 
countries [22]. Although specific selection for ESBL detection 
was not included in the EFFORT sampling and data collection 
(as for any other antibiotic), cefotaxime- and ceftazidime- 
resistant E. coli were used as a proxy for ESBL- producing 
E. coli proportion. However, the proportion of these isolates 
observed in the dataset does not resemble the proportion of 
samples or animals containing ESBL/AmpC producing E. coli, 
as indicated by EFSA, and this may explain why no significant 
associations with usage were observed.
Resistance to ciprofloxacin is used as a proxy for resist-
ance to (fluoro)quinolones, included in the list of the 
highest prioritized critically important antimicrobials for 
human medicine [21, 23]. Reduced susceptibility to cipro-
floxacin in broilers varied by country between 11.5 and 
91.5 % (Table 2) and correlated significantly (Spearman's 
rho=0.778, P=0.014) with fluoroquinolone usage over 
countries. Reduced susceptibility to ciprofloxacin in pigs 
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occurred less frequently and varied by country between 1 
and 34.4 % (Table 2). It also correlated significantly (Spear-
man's rho=0.778, P=0.014) with fluoroquinolone usage 
over countries. No correlation was observed with other 
quinolones for both broilers and fattening pigs. Fluoro-
quinolone resistance has been documented in commensal 
E. coli in livestock in Europe [24, 25], and throughout turkey 
breeding and meat flocks in the UK [26], where biosecurity 
and responsible AMU were recognized as contributors to 
restrict AMR occurrence and spread [27].
The proportion of indicator E. coli fully wild- type suscep-
tible to the entire panel of antimicrobials tested is used as 
a proxy of the overall selective pressure exerted by agri-
cultural usage of antimicrobials [28]. In general, E. coli 
isolates from fattening pigs were more susceptible than 
from other livestock (Table 2). The highest prevalence of 
fully susceptible E. coli was observed in country C in both 
broilers and fattening pigs (49–50.5 %, respectively). There 
was no significant correlation between the proportion of 
fully susceptible E. coli and AMU for broilers or pigs (Fig. 
S1) . Several speculations could be made for this correlation 
not being significant. Although the quality of the dataset 
is undisputable, this was not designed to prove an asso-
ciation between overall AMU and fully susceptible E. coli. 
Additionally, the proportion of fully susceptible E. coli is 
not a specific indicator for overall AMU. When applied to 
a very large dataset, as done by EFSA, this correlation will 
likely be very high. However, in a study like EFFORT with 
more diversity relative to the number of samples taken, this 
correlation is expected to be lower, a reason why also EFSA 
is re- evaluating how specific these composite indicators are. 
Finally, as previously reported in another publication by the 
EFFORT consortium [9], for some countries data collec-
tion on AMU was challenging, as the sample period was 
not always consistent over the year, and this may have also 
influenced this correlation.
The last indicator considered was multidrug resistance 
(MDR), i.e. resistance to three or more antimicrobials 
classes [29]. This indicator is informative in situations with 
high levels of resistance with very few isolates displaying 
full susceptibility [5]. MDR was observed in most of the 
countries, especially in broilers (58.5–90.5 %) and fattening 
turkeys (54–88.3 %) (Table 2). High MDR level in poultry 
is a well- known phenomenon, partially related to frequent 
use of antimicrobials as oral group treatments in fattening 
periods as short as 6 weeks for broilers [30]. No significant 
correlation between AMU at country level and MDR in 
broilers and fattening pigs was observed (Fig. S1). As for 
the fully susceptible E. coli indicator, the MDR indicator 
might better apply to very large datasets, in relation to 
the number of farms sampled here relative to the diver-
sity in the dataset. However, correlations between high 
MDR levels and other AMU parameters as well as specific 
farm characteristics might be significant, as investigated 
in more in depth studies from the EFFORT consortium 
[6, 31, 32]. At strain level, the most resistant E. coli of the 
entire collection was recovered from a fattening turkey of 
country H resistant to 11 antibiotics (AMP, FOT, TAZ, CIP, 
NAL, CHL, COL, GEN, SMX, TET, TGC) spanning eight 
different classes (Table S1). MDR profiles to seven different 
classes were sporadically observed in E. coli from fattening 
pigs (country I), broilers (countries H and I) and veal calves 
(country E) (Table S1).
Conclusions
A wide collection of E. coli isolates and related MIC profiles 
from different animal reservoirs was produced and analysed 
in relation with harmonized AMR indicators and AMU at 
country level. Resistance proportions varied between antimi-
crobials and animal species, and correlation with usage was 
not always significant. Where possible the results gathered 
here were compared cautiously with AMR and AMU data 
from other studies, keeping in mind the use of different meth-
odologies to describe the data.
The strength of the EFFORT project relies on AMR and AMU 
datasets gathered from the same farms. The analysis performed 
here correlates aggregated data from the same farms at country 
level for both AMU and AMR within antimicrobial classes. To 
the best of our knowledge, this was not performed before with 
data gathered from the same epidemiological unit, i.e. the farm, 
on such a scale. Even though the data is aggregated and was not 
analysed at farm level, there is still a stronger correlation than 
when correlating AMR monitoring data to AMU data at farm 
level, as regularly done in numerous reports and studies [33, 34]. 
Although it is accepted generally that AMU will cause AMR 
[34, 35], the extent to which this happens differs enormously 
per antimicrobial class, as is clearly shown by these results, also 
depending on other factors like farm management and char-
acteristics. Since Spearman's rank correlation is a quantitative 
association test, we get a feeling of the extent of the correlations 
per antimicrobial class.
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